Masimo Announces Pathway, a newborn oxygenation visualization mode

Sept. 6, 2019

Masimo has announced the launch of Pathway, a feature for the Root Patient Monitoring and Connectivity Platform. Pathway provides clinicians with a way to visualize a hospital’s recommended resuscitation protocol for a newborn’s oxygen saturation (SpO2) while continuously monitoring SpO2 and pulse rate (PR) during the first ten minutes after birth.

The company says use of Pathway is intended to help streamline clinician workflow and improve protocol adherence during this critical period. Pathway was invented by Dr. Yacov Rabi, MD, Associate Professor in the Department of Pediatrics at the Cumming School of Medicine, University of Calgary, Canada, and licensed to Masimo.

The International Liaison Committee on Resuscitation (American Heart Association) has developed treatment recommendations outlining time-based SpO2 targets that reflect a healthy newborn’s oxygenation during the first ten minutes after birth.

Current hospital practice relies on manually referencing charts or clinician recollection for adherence to protocols based on these recommendations. The ability to display local oxygen saturation targeting guidelines while still actively monitoring SpO2 and PR via Pathway’s intuitive interface is intended to help clinicians more easily adhere to their institution’s resuscitation protocols.

While Pathway is active, Root displays SpO2 values alongside a visualization of the hospital-defined SpO2 targets over time. To help clinicians track time since birth, Pathway displays an easily adjustable timer bar so that clinicians no longer need to mentally track the difference between the time of birth and the start of monitoring. Pathway can also provide hospitals with the ability to monitor and capture data involving adherence to their chosen newborn resuscitation protocols.

Pathway’s visualization on Root works in tandem with continuous SpO2 monitoring powered by Masimo SET Measure-through Motion and Low Perfusion technology, which has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Crucially for newborn health, SET has been shown to help clinicians reduce severe retinopathy of prematurity in neonates3 and in multiple studies, including the largest critical congenital heart disease (CCHD) study to date, to improve CCHD screening in newborns.